SIGN UP. CRISPR Therapeutics's quarterly revenue was down 99.9% on a year-over-year basis. Identify stocks that meet your criteria using seven unique stock screeners. You can opt out at any time. In that case, its stock would basically be worthless. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 View analysts' price targets for CRISPR Therapeutics or view top-rated stocks among Wall Street analysts. Get daily stock ideas top-performing Wall Street analysts. History; Forecast; Charts; Data; Market; Q&A; Comments > Page 1: CRISPR Therapeutics AG (CRSP) Forecast … View CRISPR Therapeutics' earnings history. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. The CRSP/COMPUSTAT Merged Database allows for concurrent database access to CRSP’s stock data and Compustat’s fundamental data. Please log in to your account or sign up in order to add this asset to your watchlist. Zgutowicz predicts that by year-end, 12% of Shopify's North American revenue will be coming from SFN, driving 21% gains for the stock. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Fundamental company data provided by Zacks Investment Research. Earnings for CRISPR Therapeutics are expected to decrease in the coming year, from ($4.97) to ($5.13) per share. View which stocks have been most impacted by COVID-19. *Stock price forecasts are predicted by Deep Learning processes by technical analysis, shouldn't been used for investment decision. CRSP CRISPR Therapeutics AG Statement of Changes in Beneficial Ownership (4) FORM 4 [ ] Check this box if no longer subject to Section 16. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. CRISPR Therapeutics AG (NAS : CRSP) 1:01 AM ET. Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Tony W Ho. Today, CRISPR is already … CRSP | Complete CRISPR Therapeutics AG stock news by MarketWatch. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. (Add your “outperform” vote. CRISPR Therapeutics AG CRSP was a big mover last session, as the company saw its shares rise more than 6% on the day. Top institutional investors include Nikko Asset Management Americas Inc. (5.39%), BlackRock Inc. (1.65%), Federated Hermes Inc. (0.89%), Wells Fargo & Company MN (0.65%), Lord Abbett & CO. LLC (0.43%) and Jennison Associates LLC (0.39%). Detail Earnings Estimate History contains forecast … ... NASDAQ: CRSP $160.20 down $-7.35 (-4.39%) … Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 98.9 % based on the past 4 years of stock performance. Start Now for $1 >>, Jessica Silver-Greenberg and Michael Corkery. View which stocks are hot on social media with MarketBeat's trending stocks report. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . The company can be reached via phone at 41-41-561-3277 or via email at [email protected]. Direxion Daily Gold Miners Index Bull 2x Shares, Unlock HIDDEN Features! Receive a free world-class investing education from MarketBeat. 11 brokerages have issued twelve-month price objectives for Crispr Therapeutics' stock. Lightning fast & can cost as Little as 5¢ or even 1¢...", Co-Founder & Scientific Advisory Board Member, Scientific Founder & Advisory Board Member, Start Your Risk-Free Trial Subscription Here, 3 Consumer Discretionary Stocks Ready to Run, 3 Dating App Stocks for Investors to Love, Fox hosts Dobbs, Bartiromo strike back in voting fraud suit, Georgia governor urges Biden to block battery maker penalty, Amazon sues NY attorney general to stop virus probe, General Motors settles with California for $5.75M, 3 Oil & Gas Stocks Worth Watching in 2021, U.S. Steel Stock is an Economic Recovery Buy Here, American Axle Manufacturing Stock is an Automotive Recovery and Electrification Play, 3 Health Care Stocks That Could Double by Year End, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, Interesting CRSP Put And Call Options For April 1st, Bear of the Day: CRISPR Therapeutics (CRSP), Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day, CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day. Specifically, they have bought $0.00 in company stock and sold $66,444,533.00 in company stock. Global Genome Editing Market Research Report to 2021 | Growing Rapidly with Modern Trends, Development Status, Investment Opportunities, Share, Revenue, Future Demand and Forecast to 2025 … The consensus among Wall Street research analysts is that investors should "buy" CRISPR Therapeutics stock. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland. !! About the Stratasys Ltd. stock forecast. View institutional ownership trends for CRISPR Therapeutics. CRISPR Therapeutics AG Stock Price Forecast, "CRSP" Predictons for2025 ... CRISPR Therapeutics AG Stock Forecast and Price Prognosis Data for 2025 . The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. This suggests a possible upside of 27.2% from the stock's current price. Vote “Underperform” if you believe CRSP will underperform the S&P 500 over the long term. Global CRISPR Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2025 – Express Journal Posted: August 1, 2020 at 8:59 pm Global CRISPR … Future price of the stock is predicted at 252.773141$ (53.121% ) after a year according to our prediction system. This suggests that the stock has a possible downside of 12.0%. During the same period in the previous year, the firm earned $2.40 earnings per share. When was CRSP stock first added to ArkG and ArkK? Learn more. MarketBeat just released five new trading ideas, but CRISPR Therapeutics wasn't one of them. As of January 29th, there was short interest totaling 2,950,000 shares, a decline of 19.0% from the January 14th total of 3,640,000 shares. The official website for CRISPR Therapeutics is www.crisprtx.com. View analyst ratings for CRISPR Therapeutics or view top-rated stocks. Feb 04, 2021 (AmericaNewsHour) -- Global Genome Editing Market - Drivers, Restraints, Opportunities, Trends, and Forecast, 2019-2025… In the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. CRISPR Therapeutics has a market capitalization of $11.47 billion and generates $289.59 million in revenue each year. 16 Wall Street analysts have issued 1 year price targets for CRISPR Therapeutics' stock. The Titan project is targeting a 2024 or 2025 push to develop an … Five years from now, CRISPR Therapeutics (NASDAQ:CRSP) may well be a household name as a result of awe-inspiring early results from its in vivo therapies. Looking for new stock ideas? CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. Want to see which stocks are moving? CRISPR Therapeutics employs 304 workers across the globe. On average, they anticipate CRISPR Therapeutics' share price to reach $141.79 in the next twelve months. This means that if you invested $100 now, your current investment may be worth 153.121$ on 2022 February 13, Sunday. What happens next will shock you…". All rights reserved. Do Not Sell My Information. View insider buying and selling activity for CRISPR Therapeutics or view top insider-selling stocks. CRISPR Therapeutics' stock is owned by a number of retail and institutional investors. HOME MARKET TRADE PRICING DOWNLOAD HELP. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. This breaks the recent trend of the company, as the stock … Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. CRSP stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., FIL Ltd, WBI Investments, Nia Impact Advisors LLC, Brevan Howard Capital Management LP, EMJ Capital Ltd., LPL Financial LLC, and BlackRock Inc.. View insider buying and selling activity for CRISPR Therapeutics or or view top insider-buying stocks. Vote “Outperform” if you believe CRSP will outperform the S&P 500 over the long term. The company's average rating score is 2.56, and is based on 11 buy ratings, 3 hold ratings, and 2 sell ratings. CRISPR Therapeutics has received a consensus rating of Buy. Since then, CRSP shares have increased by 272.1% and is now trading at $161.05. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. View all of CRSP's competitors. Compare Top Brokerages Here. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. ; CRISPR Therapeutics AG has risen higher in 3 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 75 % ; Is CRISPR Therapeutics AG Stock … Learn everything you need to know about successful options trading with this three-part video course. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Based on analysts offering 12 month price targets for CRSP in the last 3 months. Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Learn more. To see all exchange delays and terms of use please see disclaimer. See what's happening in the market right now with MarketBeat's real-time news feed. Webull offers CRSP stock news, real time Crispr Therapeut news help you invest smart. (CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. CRSP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bank of New York Mellon Corp, Federated Hermes Inc., Wells Fargo & Company MN, Columbus Circle Investors, Capital Advisors Inc. OK, Teacher Retirement System of Texas, and Hussman Strategic Advisors Inc.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho. View CRISPR Therapeutics' (NASDAQ:CRSP) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by $0.14. Our site uses a custom algorithm based on Deep Learning that helps our users to decide if CRSP could be a good portfolio addition. Man Gets Into a Tesla… What Happens Next Will Shock Everyone (Video), "Hi, I'm Jeff Brown… I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project… About the CRISPR Therapeutics AG stock forecast. CRISPR Therapeutics AG has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. (Add your “underperform” vote.). As of 2021 February 07, Sunday … CRISPR Therapeutics has received 53.11% “outperform” votes from our community. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Shares of CRSP can be purchased through any online brokerage account. Past success does not guarantee future profit !! These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. News. 5 days ago JS predicted that CRSP for Feb. 1st is going $166.34 (-1.46%) 6 days ago Cesar predicted that CRSP for Feb. 1st is going Rank: 1 week ago JS predicted that CRSP … Learn about financial terms, types of investments, trading strategies and more. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. The move came on solid volume too with far more shares changing hands than in a normal session. 1 year CRISPR Therapeutics AG Forecast: 252.773141 *, 5 year CRISPR Therapeutics AG Forecast: 907.842 *. View Analyst Price Targets for Crispr Therapeutics. CRISPR Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. CRISPR Therapeutics AG Stock Forecast. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. CRISPR Therapeutics AG () Stock Market info Recommendations: Buy or sell CRISPR Therapeutics AG stock? ), CRISPR Therapeutics has received 339 “underperform” votes. Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts GlobeNewswire. Shifting the Projection Time Period from 2015-2025 to 2018-2028 . One share of CRSP stock can currently be purchased for approximately $161.05. View our earnings forecast for CRISPR Therapeutics. ... predictions and my price target for the stock in the next years. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. MarketBeat's community ratings are surveys of what our community members think about CRISPR Therapeutics and other stocks. ... (GLOBE NEWSWIRE) -- The "Procurement Software Market - Growth, Trends, Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. Only 17.10% of the stock of CRISPR Therapeutics is held by insiders. By 2025, this brand new service could be providing … 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. This means that this stock is suited as a new addition to your portfolio as trading bullish markets is always a lot easier. Wall Street Stock Market & Finance report, prediction for the future: You'll find the CRISPR Therapeutics AG share forecasts, stock quote and buy / sell signals below.According to present data CRISPR Therapeutics AG's CRSP … Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The database provides the historical matching of CRSP price, distribution, and total return data with Compustat fundamental data. Their forecasts range from $21.00 to $72.50. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. Export data to Excel for your own analysis. LOG IN. You may vote once every thirty days. As of 2021 February 10, Wednesday current price of SSYS stock is 53.105$ and our data indicates that the asset price has been stagnating for the past 1 year (or since … On average, they anticipate Crispr Therapeutics' stock price to reach $48.9167 in the next twelve months. All users should speak with their financial advisor before buying or selling any securities. There are currently 2 sell ratings, 3 hold ratings and 11 buy ratings for the stock. QQQ 332.75 (-0.23%) AAPL 135.39 (-0.46%) Get short term trading ideas from the MarketBeat Idea Engine. CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). The firm earned $0.15 million during the quarter, compared to analysts' expectations of $2.22 million. CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 17th 2021. What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock. High institutional ownership can be a signal of strong market trust in this company. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. CRISPR Therapeutics saw a decline in short interest during the month of January. The procurement software market is expected to register a CAGR of 10.2% during the forecast period (2020 - 2025… most recent headlines. Some companies that are related to CRISPR Therapeutics include Biogen (BIIB), Seagen (SGEN), BioNTech (BNTX), Novozymes A/S (NVZMY), Novavax (NVAX), argenx (ARGX), Bio-Techne (TECH), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Adaptive Biotechnologies (ADPT), Fate Therapeutics (FATE), Vir Biotechnology (VIR), Twist Bioscience (TWST) and Denali Therapeutics (DNLI). Introducing CRISPR Therapeutics (NASDAQ:CRSP), The Stock That Soared 424% In The Last Three Years - Simply Wall St - October 18th, 2020 CRISPR And CRISPR-Associated (Cas) Genes Market Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast … Based on an average daily trading volume, of 1,920,000 shares, the days-to-cover ratio is presently 1.5 days. All quotes are in local exchange time. CRISPR Therapeutics does not currently pay a dividend. © American Consumer News, LLC dba MarketBeat® 2010-2021. These updated JCHS household projections are also for years 2018-2028 and 2028-2038, three years later than the previous projections for 2015-2025 and 2025 … CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. CRISPR Therapeutics AG CRSP was a big mover last session, as the company saw its shares rise more than 6% on the day. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. CRISPR Therapeutics does not have a long track record of dividend growth. Size, Drivers, Trends & Forecast 2025. So this probably isn't a name that investors will want to own in a retirement portfolio. CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? CRISPR Therapeutics has received 384 “outperform” votes. As of 2021 February 13, Saturday current price of CRSP stock is 158.560$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception). View our full suite of financial calendars and market data tables, all for free. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 20.72% and a negative net margin of 273.10%. View real-time stock prices and stock quotes for a full financial overview. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. CRISPR Therapeutics has a P/B Ratio of 9.46. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager. View CRISPR Therapeutics' Short Interest. The P/E ratio of CRISPR Therapeutics is -49.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.